Patents by Inventor Dan T. Stinchcomb

Dan T. Stinchcomb has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20140134205
    Abstract: Embodiments herein report compositions, methods and uses for dengue-4 (DENV-4) virus constructs. Some embodiments concern a composition that includes, but is not limited to, DENV-4 virus constructs alone or in combination with other constructs, can be used in a vaccine composition to induce an immune response in a subject. In certain embodiments, compositions can include constructs of more than one serotypes of dengue virus, such as dengue-1 virus, dengue-2 virus, or dengue-3 virus in combination with DENV-4 virus constructs disclosed herein. In other embodiments, DENV-4 constructs disclosed herein can be combined in a composition with other flavivirus constructs to generate a vaccine against more than one flavivirus. Other embodiments provide methods and uses for DENV-4 virus constructs in vaccine compositions that when administered to a subject induce an immune response in the subject against DENV-4 that is improved by modified constructs compared to other vaccine compositions.
    Type: Application
    Filed: November 8, 2013
    Publication date: May 15, 2014
    Applicants: The Government of the United States of America as Represented by the Secretary of Health & Human S, INVIRAGEN, INC.
    Inventors: Jill A. Livengood, Claire Y. Huang, Timothy D. Powell, Dan T. Stinchcomb, Jorge Osorio
  • Publication number: 20130209513
    Abstract: Embodiments of the present invention generally disclose methods, compositions and uses for generating and expressing poxvirus constructs. In some embodiments, constructs may contain an influenza virus gene segment. In certain embodiments, methods generally relate to making and using compositions of constructs including, but not limited to, poxvirus vaccine compositions having two or more influenza gene segments. In other embodiments, vaccine compositions are reported of use in a subject.
    Type: Application
    Filed: July 20, 2012
    Publication date: August 15, 2013
    Inventors: Dan T. Stinchcomb, Jorge E. Osorio, Timothy D. Powell, Jeremy C. Jones, Joseph N. Brewoo
  • Publication number: 20130149338
    Abstract: Embodiments of the present invention report compositions and methods for vaccinating a subject against all dengue virus serotypes. In some embodiments, multiple vaccine compositions may be administered to a subject in different anatomical locations in order to induce a rapid response to all dengue virus serotypes. In certain embodiments, administration of two or more vaccine compositions to a subject against all dengue virus serotypes may include two or more routes of administration.
    Type: Application
    Filed: June 10, 2012
    Publication date: June 13, 2013
    Inventors: Dan T. STINCHCOMB, Jorge E. OSORIO, Charalambos D. PARTIDOS, Joseph N. BREWOO
  • Publication number: 20130136767
    Abstract: Embodiments of the present invention generally disclose methods, compositions and uses for generating and expressing poxvirus constructs. In some embodiments, constructs may contain an influenza virus gene segment. In certain embodiments, methods generally relate to making and using compositions of constructs including, but not limited to, poxvirus vaccine compositions. In other embodiments, vaccine compositions are reported of use in a subject.
    Type: Application
    Filed: November 22, 2010
    Publication date: May 30, 2013
    Inventors: Dan T. Stinchcomb, Jorge E. Osorio, Timothy D. Powell, Jeremy Jones
  • Publication number: 20130034583
    Abstract: Embodiments of the present invention generally disclose methods, compositions and uses for generating and expressing enterobacterial-associated peptides. In some embodiments, enterobacterial-associated peptides include, but are not limited to plague-associated peptides. In certain embodiments, methods generally relate to making and using compositions of constructs including, but not limited to, attenuated or modified vaccinia virus vectors expressing enterobacterial-associated peptides. In other embodiments, vaccine compositions are reported of use in a subject.
    Type: Application
    Filed: November 24, 2010
    Publication date: February 7, 2013
    Applicant: INVIRAGEN, INC.
    Inventors: Dan T. Stinchcomb, Jorge E. Osorio, Timothy D. Powell, Joseph N. Brewoo
  • Patent number: 8088903
    Abstract: The present invention relates to flea head, nerve cord, hindgut and Malpighian tubule proteins; to flea head, nerve cord, hindgut and Malpighian tubule nucleic acid molecules, including those that encode such flea head, nerve cord, hindgut and Malpighian tubule proteins; to antibodies raised against such flea head, nerve cord, hindgut and Malpighian tubule proteins; and to compounds that inhibit flea head, nerve cord, hindgut and Malpighian tubule protein activity. The present invention also includes methods to obtain such proteins, nucleic acid molecules, antibodies, and inhibitory compounds. Also included in the present invention are therapeutic compositions comprising proteins, nucleic acid molecules, antibodies, or protective compounds derived from proteins of the present invention as well as the use of such therapeutic compositions to protect animals from flea infestation.
    Type: Grant
    Filed: December 1, 2006
    Date of Patent: January 3, 2012
    Assignee: Heska Corporation
    Inventors: Kevin S. Brandt, Patrick J. Gaines, Dan T. Stinchcomb, Nancy Wisnewski
  • Patent number: 8084039
    Abstract: Embodiments herein relate to compositions of and methods for live viruses. In certain embodiments, a live, attenuated virus composition includes, but is not limited to, one or more live, attenuated viruses and compositions to reduce inactivation and/or degradation of the live, attenuated virus. In other embodiments, the live, attenuated virus composition may be a vaccine composition. In yet other compositions, a live, attenuated virus composition may include at least one carbohydrate, at least one protein and at least one high molecular weight surfactants for reducing inactivation and/or degradation of the live, attenuated virus.
    Type: Grant
    Filed: April 4, 2008
    Date of Patent: December 27, 2011
    Assignee: Inviragen, Inc.
    Inventors: Dan T. Stinchcomb, Jorge E. Osorio, O'Neil Wiggan
  • Patent number: 8029776
    Abstract: The present invention relates to a method to introduce a nucleic acid molecule into a felid by administration of a nucleic acid-cationic lipid complex composition. The method includes the step of administering to the felid, by a parenteral route, a nucleic acid-cationic lipid complex to elicit and/or enhance an immune response. In one embodiment, this method enhances the immune response in a felid compared to a method in which a naked DNA vaccine is administered to a felid. Also provided is a method to deliver a nucleic acid to a felid. This method comprises parenterally administering to the felid a composition that includes a nucleic acid molecule complexed with a cationic lipid.
    Type: Grant
    Filed: October 3, 2007
    Date of Patent: October 4, 2011
    Assignee: Heska Corporation
    Inventors: Joel R. Haynes, Ramani S. Wonderling, Dan T. Stinchcomb
  • Publication number: 20100303860
    Abstract: Embodiments of the present invention report compositions and methods for vaccinating a subject against dengue viruses. In some embodiments, vaccine compositions may be administered by intradermal introduction. In certain embodiments, intradermal introduction in a subject of a vaccine against dengue virus may include one or more intradermal boosts after initial vaccination. Other embodiments include intradermal injection of a vaccine composition against dengue virus wherein the composition provides protection against two or more of DEN-1, DEN-2, DEN-3 and DEN-4.
    Type: Application
    Filed: May 28, 2010
    Publication date: December 2, 2010
    Inventors: Dan T. STINCHCOMB, Jorge E. OSORIO, Charalambos D. PARTIDOS, Joseph N. BREWOO
  • Publication number: 20100144015
    Abstract: Embodiments herein report methods, compositions and uses for inducing and/or accelerating viral growth. In certain embodiments, methods, compositions and uses generally related to copolymer compositions for inducing viral growth, reducing lag time and/or increasing viral plaque size. In other embodiments, methods, compositions and uses of copolymer compositions can be for inducing flaviviral growth, reducing lag in growth and/or increasing plaque size.
    Type: Application
    Filed: December 4, 2009
    Publication date: June 10, 2010
    Inventors: Dan T. Stinchcomb, Jill A. Livengood, O'Neil Wiggan, Richard Kinney, Jorge Osorio
  • Publication number: 20090186008
    Abstract: The present invention relates to flea head, nerve cord, hindgut and Malpighian tubule proteins; to flea head, nerve cord, hindgut and Malpighian tubule nucleic acid molecules, including those that encode such flea head, nerve cord, hindgut and Malpighian tubule proteins; to antibodies raised against such flea head, nerve cord, hindgut and Malpighian tubule proteins; and to compounds that inhibit flea head, nerve cord, hindgut and Malpighian tubule protein activity. The present invention also includes methods to obtain such proteins, nucleic acid molecules, antibodies, and inhibitory compounds. Also included in the present invention are therapeutic compositions comprising proteins, nucleic acid molecules, or protective compounds derived from proteins of the present invention as well as the use of such therapeutic compositions to protect animals from flea infestation.
    Type: Application
    Filed: February 20, 2008
    Publication date: July 23, 2009
    Inventors: KEVIN S. BRANDT, PATRICK J. GAINES, DAN T. STINCHCOMB, NANCY WISNEWSKI
  • Publication number: 20090060948
    Abstract: The present invention relates to a method to introduce a nucleic acid molecule into a fetid by administration of a nucleic acid-cationic lipid complex composition. The method includes the step of administering to the felid, by a parenteral route, a nucleic acid-cationic lipid complex to elicit and/or enhance an immune response. In one embodiment, this method enhances the immune response in a fetid compared to a method in which a naked DNA vaccine is administered to a felid. Also provided is a method to deliver a nucleic acid to a felid. This method comprises parenterally administering to the fetid a composition that includes a nucleic acid molecule complexed with a cationic lipid.
    Type: Application
    Filed: October 3, 2007
    Publication date: March 5, 2009
    Inventors: Joel R. Haynes, Ramani S. Wonderling, Dan T. Stinchcomb
  • Publication number: 20080248551
    Abstract: Embodiments herein relate to compositions of and methods for live viruses. In certain embodiments, a live, attenuated virus composition includes, but is not limited to, one or more live, attenuated viruses and compositions to reduce inactivation and/or degradation of the live, attenuated virus. In other embodiments, the live, attenuated virus composition may be a vaccine composition. In yet other compositions, a live, attenuated virus composition may include at least one carbohydrate, at least one protein and at least one high molecular weight surfactants for reducing inactivation and/or degradation of the live, attenuated virus.
    Type: Application
    Filed: April 4, 2008
    Publication date: October 9, 2008
    Inventors: Dan T. Stinchcomb, Jorge E. Osorio, O'Neil Wiggan
  • Patent number: 7314627
    Abstract: The present invention relates to a method to introduce a nucleic acid molecule into a felid by administration of a nucleic acid-cationic lipid complex composition. The method includes the step of administering to the felid, by a parenteral route, a nucleic acid-cationic lipid complex to elicit and/or enhance an immune response. In one embodiment, this method enhances the immune response in a felid compared to a method in which a naked DNA vaccine is administered to a felid. Also provided is a method to deliver a nucleic acid to a felid. This method comprises parenterally administering to the felid a composition that includes a nucleic acid molecule complexed with a cationic lipid.
    Type: Grant
    Filed: June 9, 2004
    Date of Patent: January 1, 2008
    Assignee: Heska Corporation
    Inventors: Joel R. Haynes, Ramani S. Wonderling, Dan T. Stinchcomb
  • Patent number: 6770282
    Abstract: The present invention relates to a method to introduce a nucleic acid molecule into a felid by administration of a nucleic acid-cationic lipid complex composition. The method includes the step of administering to the felid, by a parenteral route, a nucleic acid-cationic lipid complex to elicit and/or enhance an immune response. In one embodiment, this method enhances the immune response in a felid compared to a method in which a naked DNA vaccine is administered to a felid. Also provided is a method to deliver a nucleic acid to a felid. This method comprises parenterally administering to the felid a composition that includes a nucleic acid molecule complexed with a cationic lipid.
    Type: Grant
    Filed: August 10, 2001
    Date of Patent: August 3, 2004
    Assignee: Heska Corporation
    Inventors: Joel R. Haynes, Ramani S. Wonderling, Dan T. Stinchcomb
  • Publication number: 20040102413
    Abstract: The present invention relates to nucleic acid molecules which modulate the synthesis, expression and/or stability of an RNA encoding one or more protein subunits of telomerase enzyme.
    Type: Application
    Filed: November 13, 2003
    Publication date: May 27, 2004
    Applicant: Sirna Therapeutics, Inc.
    Inventors: James McSwiggen, Bharat M. Chowrira, Dan T. Stinchcomb
  • Publication number: 20040067516
    Abstract: The present invention relates to flea head, nerve cord, hindgut and Malpighian tubule proteins; to flea head, nerve cord, hindgut and Malpighian tubule nucleic acid molecules, including those that encode such flea head, nerve cord, hindgut and Malpighian tubule proteins; to antibodies raised against such flea head, nerve cord, hindgut and Malpighian tubule proteins; and to compounds that inhibit flea head, nerve cord, hindgut and Malpighian tubule protein activity. The present invention also includes methods to obtain such proteins, nucleic acid molecules, antibodies, and inhibitory compounds. Also included in the present invention are therapeutic compositions comprising proteins, nucleic acid molecules, antibodies, or protective compounds derived from proteins of the present invention as well as the use of such therapeutic compositions to protect animals from flea infestation.
    Type: Application
    Filed: July 16, 2003
    Publication date: April 8, 2004
    Inventors: Kevin S. Brandt, Patrick J. Gaines, Dan T. Stinchcomb, Nancy Wisnewski
  • Publication number: 20030207837
    Abstract: The present invention relates to nucleic acid molecules which block synthesis and/or expression of an mRNA encoding B7-1, B7-2, B7-3 and/or CD40.
    Type: Application
    Filed: May 19, 2003
    Publication date: November 6, 2003
    Applicant: Ribozyme Pharmaceuticals, Inc.
    Inventors: Dan T. Stinchcomb, Thale Jarvis, James McSwiggen
  • Patent number: 6566127
    Abstract: The present invention relates to nucleic acid molecules which modulate the synthesis, expression and/or stability of an mRNA encoding one or more receptors of vascular endothelial growth factor.
    Type: Grant
    Filed: August 10, 1999
    Date of Patent: May 20, 2003
    Assignees: Ribozyme Pharmaceuticals, Inc., Chiron Corporation
    Inventors: Pamela Pavco, James A. McSwiggen, Dan T. Stinchcomb, Jaime Escobedo
  • Publication number: 20030073827
    Abstract: The present invention relates to flea head, nerve cord, hindgut and Malpighian tubule proteins; to flea head, nerve cord, hindgut and Malpighian tubule nucleic acid molecules, including those that encode such flea head, nerve cord, hindgut and Malpighian tubule proteins; to antibodies raised against such flea head, nerve cord, hindgut and Malpighian tubule proteins; and to compounds that inhibit flea head, nerve cord, hindgut and Malpighian tubule protein activity. The present invention also includes methods to obtain such proteins, nucleic acid molecules, antibodies, and inhibitory compounds. Also included in the present invention are therapeutic compositions comprising proteins, nucleic acid molecules, or protective compounds derived from proteins of the present invention as well as the use of such therapeutic compositions to protect animals from flea infestation.
    Type: Application
    Filed: November 21, 2001
    Publication date: April 17, 2003
    Inventors: Kevin S. Brandt, Patrick J. Gaines, Dan T. Stinchcomb, Nancy Wisnewski